Daniel D. Von Hoff, M.D., F.A.C.P. is currently Physician in Chief, Distinguished Professor Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for Scottsdale Healthcare’s Clinical Research Institute and is the Medical Director of Research at McKesson Specialty Health and the Scientific Medical Officer for US Oncology Research. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.
Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer.
Dr. Von Hoff has published more than 648 papers, 138 book chapters and over 1085 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.
Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop to train young clinical investigators. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
Nicholas J. Robert, M.D., is a graduate of the McGill Medical School in Montreal. He completed an internship and residency in medicine at the Royal Victoria Hospital and went on to complete a second residency in Anatomic Pathology at Massachusetts General Hospital, where he was Chief Resident. Dr. Robert continued his training during fellowships in Hematology at Brigham and Women’s Hospital and Medical Oncology at Dana-Farber Cancer Institute, both affiliated with Harvard Medical School.
Dr. Robert is a member of several organizations including the American Society of Clinical Oncology, and the US Oncology Research Network. Highly interested in advancing oncology research, Dr. Robert also serves as chairman of the American Society of Clinical Oncology (ASCO) Community Research Forum. Dr. Robert has been recognized as a Top Doctor by Washingtonian magazine for more then fifteen years. He has also been listed as a Castle Connolly Top Doctor with the distinct honor of being named one of the top 1% of oncologists in the country by U.S. News and World Report.
Dr. Robert is the author of over 100 publications with major research interests in breast cancer and primary brain tumors. He is a reviewer for several medical journals as well as the recipient of numerous research grants. Previously the Clinical Director of Medical Oncology at Tufts University – New England Medical Center, he currently works with Virginia Cancer Specialists in Northern Virginia. He has also served as Chairman of the Cancer Committee and Section Chief of Hematology/Oncology in the Department of Medicine at Inova Fairfax Hospital.
Dr. Robert takes great pleasure in developing close relationships with his patients and discussing the most cutting-edge breast cancer therapies with them so that they can understand all their options. In this video, he emphasizes the importance of patient involvement in his/her own treatment.